Targeting Strategies for Enhancing Paclitaxel Specificity in Chemotherapy
Authors:
Open Access
- 29 March 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 9
Abstract
Paclitaxel (PTX) has been used for cancer treatment for decades and has become one of the most successful chemotherapeutics in the clinic and financially. However, serious problems with its use still exist, owing to its poor solubility and non-selective toxicity. With respect to these issues, recent advances have addressed the water solubility and tumor specificity related to PTX application. Many measures have been proposed to remedy these limitations by enhancing tumor recognition via ligand-receptor-mediated targeting as well as other associated strategies. In this review, we investigated various kinds of ligands that have emerged as PTX tumor-targeting tools. In particular, this article highlights small molecule-, protein-, and aptamer-functionalized conjugates and nanoparticles (NPs), providing a promising approach for PTX-based individualized treatment prospects.Keywords
This publication has 174 references indexed in Scilit:
- Nucleolin Targeting AS1411 Modified Protein Nanoparticle for Antitumor Drugs DeliveryMolecular Pharmaceutics, 2013
- NMR identification of endogenous metabolites interacting with fatted and non-fatted human serum albumin in blood plasma: Fatty acids influence the HSA–metabolite interactionJournal of Magnetic Resonance, 2013
- RNA-binding protein nucleolin in diseaseRNA Biology, 2012
- Tumor-Targeting Drug Delivery of New-Generation TaxoidsFuture Medicinal Chemistry, 2011
- Novel Aptamer-Nanoparticle Bioconjugates Enhances Delivery of Anticancer Drug to MUC1-Positive Cancer Cells In VitroPLOS ONE, 2011
- Phase 3 study of docosahexaenoic acid–paclitaxel versus dacarbazine in patients with metastatic malignant melanomaAnnals of Oncology, 2010
- Nanoparticle-based theranostic agentsAdvanced Drug Delivery Reviews, 2010
- Synthesis and Preliminary Biological Evaluation of High-Drug-Load Paclitaxel-Antibody Conjugates for Tumor-Targeted ChemotherapyJournal of Medicinal Chemistry, 2009
- Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep‐2British Journal of Pharmacology, 2008
- Anticancer Therapeutics: Targeting Macromolecules and Nanocarriers to Hyaluronan or CD44, a Hyaluronan ReceptorMolecular Pharmaceutics, 2008